# US 2012/0252016 A1 · Optimized oligonucleotides and methods of using same for the detection, isolation, amplification, quantitation, monitoring, screening, and sequencing of group b streptococcus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252016 A1
- Document ID: US20120252016A1
- Status: Published application
- Kind: A1
- Application number: 13/424,022
- Filed: 2012-03-19
- Published: 2012-10-04
- Earliest claimed: 2011-04-04
- Assignees: Intelligent Medical Devices, Inc.
- Inventors: Damien Slater; Chesley Leslin; Juan Anzola; David Dolinger; Alice A. Jacobs
- Web page: https://patentgrep.com/patent/US20120252016A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are oligonucleotides useful for detecting, isolating, amplifying, quantitating, monitoring, screening and sequencing GBS genes and methods of using the described oligonucleotides.

## Claims

### Claim 1

An isolated nucleic acid sequence comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-64.

### Claim 2

A method of hybridizing one or more isolated nucleic acid sequences comprising a sequence selected from the group consisting of: SEQ ID NOS: 1-35 to a GBS sequence, comprising contacting one or more isolated nucleic acid sequences to a sample comprising the GBS sequence under conditions suitable for hybridization.

### Claim 3 (depends on 2)

The method of claim 2, wherein the GBS sequence is a genomic sequence, a template sequence, a sequence derived from an artificial construct or an artificially synthesized sequence.

### Claim 4 (depends on 2)

The method of claim 2, further comprising the isolation of nucleic acid sequences containing a GBS sequence.

### Claim 5 (depends on 2)

The method of claim 2, further comprising detecting the hybridized GBS sequence.

### Claim 6 (depends on 2)

The method of claim 2, further comprising quantitating the hybridized GBS sequence.

### Claim 7 (depends on 2)

The method of claim 2, further comprising sequencing the hybridized GBS sequence.

### Claim 8 (depends on 2)

The method of claim 2, further comprising monitoring and/or screening for the presence of the hybridized GBS sequence.

### Claim 9

A primer set comprising at least one forward primer selected from the group consisting of SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33, and at least one reverse primer selected from the group consisting of SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.

### Claim 10 (depends on 9)

The primer set of claim 9, wherein the primer set is selected from the group consisting of: Groups 1-13 of Table 2.

### Claim 11

A method of producing a nucleic acid product, comprising contacting one or more isolated nucleic acid sequences selected from the group consisting of SEQ ID NOS: 1, 3, 4, 6, 7, 8, 10, 11, 13, 14, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 32, 33 and 35 to a sample comprising a GBS sequence under conditions suitable for nucleic acid polymerization.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nucleic acid product is an amplicon produced using at least one forward primer selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33 and at least one reverse primer selected from the group consisting of SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.

### Claim 13 (depends on 2)

The method of claim 2, wherein the GBS sequences are selected from the group consisting of: neuA and/or cspA and/or cylE and/or hylB and/or mreA and/or ptsI.

### Claim 14 (depends on 11)

The method of claim 11, further comprising a probe that hybridizes to the nucleic acid product.

### Claim 15 (depends on 14)

The probe of claim 14, wherein the probe comprises a sequence selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34.

### Claim 16 (depends on 14)

The probe of claim 14, wherein the probe is labeled with a detectable label selected from the group consisting of: a fluorescent label, a chemiluminescent label, a quencher, a radioactive label, biotin, mass tags and gold.

### Claim 17

A method for detecting a GBS sequence in a sample, comprising:
a) contacting the sample with at least one forward primer comprising a sequence selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33, and at least one reverse primer comprising a sequence selected from the group consisting of: SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35 under conditions such that nucleic acid amplification occurs to yield an amplicon; and
b) contacting the amplicon with one or more probes comprising one or more sequences selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions such that hybridization of the probe to the amplicon occurs;
wherein hybridization of the probe is indicative of GBS in the sample.

### Claim 18 (depends on 17)

The method of claim 17, wherein each of the one or more probes is labeled with a different detectable label.

### Claim 19 (depends on 17)

The method of claim 17, wherein the one or more probes are labeled with the same detectable label.

### Claim 20 (depends on 17)

The method of claim 17, wherein the sample is selected from the group consisting of: blood, serum, plasma, enriched peripheral blood mononuclear cells, fecal material, urine, neoplastic or other tissue obtained from biopsies, cerebrospinal fluid, saliva, fluids collected from the ear, eye, mouth, and respiratory airways, sputum, stool, skin, gastric secretions, oropharyngeal swabs, nasopharyngeal swabs, throat swabs, peri-rectal swabs, rectal swabs, vaginal swabs, nasal aspirates, nasal wash, renal tissue, and fluid therefrom including perfusion media, pure cultures of bacterial fungal isolates, fluids and cells obtained by the perfusion of tissues of both human and animal origin, and fluids and cells derived from the culturing of human cells, including human stem cells and human cartilage or fibroblasts, pure cultures of bacterial fungal isolates, and swabs or washes of environmental surfaces, or other samples derived from environmental surfaces or other samples derived from environmental surfaces.

### Claim 21 (depends on 17)

The method of claim 17, wherein the sample is from a human.

### Claim 22 (depends on 17)

The method of claim 17, wherein the sample is non-human in origin.

### Claim 23 (depends on 17)

The method of claim 17, wherein the sample is derived from an inanimate object.

### Claim 24 (depends on 17)

The method of claim 17, wherein the at least one forward primer, the at least one reverse primer and the one or more probes are selected from the group consisting of: Groups 1-13 of Table 2.

### Claim 25 (depends on 17)

The method of claim 17, further comprising quantitating a GBS sequence in a sample.

### Claim 26

A kit for detecting a GBS sequence in a sample, comprising one or more probes comprising a sequence selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34.

### Claim 27 (depends on 26)

The kit of claim 26, further comprising:
a) at least one forward primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33; and
b) at least one reverse primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.

### Claim 28 (depends on 26)

The kit of claim 26, further comprising a positive control and/or a process control and/or a negative control.

### Claim 29 (depends on 28)

The kit of claim 28, wherein the positive control sequence consists of SEQ ID NO: 36.

### Claim 30 (depends on 26)

The kit of claim 26, further comprising reagents for detecting and/or quantitating and/or monitoring and/or screening and/or sequencing a GBS sequence in the sample.

### Claim 31 (depends on 26)

The kit of claim 26, wherein the one or more probes are labeled with different detectable labels.

### Claim 32 (depends on 26)

The kit of claim 26, wherein the one or more probes are labeled with the same detectable label.

### Claim 33 (depends on 27)

The kit of claim 27, wherein the at least one forward primer and the at least one reverse primer are selected from the group consisting of: Groups 1-13 of Table 2.

### Claim 34

A method of diagnosing a GBS-associated colonization, condition, syndrome or disease, comprising:
a) contacting a sample with at least one forward and reverse primer set selected from the group consisting of: Groups 1-13 of Table 2;
b) conducting an amplification reaction, thereby producing an amplicon; and
c) detecting the amplicon using one or more probes selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34;
wherein the detection of an amplicon is indicative of the presence of GBS in the sample.

### Claim 35 (depends on 34)

The method of claim 34, wherein the sample is selected from the group consisting of: blood, serum, plasma, enriched peripheral blood mononuclear cells, fecal material, urine, neoplastic or other tissue obtained from biopsies, cerebrospinal fluid, saliva, fluids collected from the ear, eye, mouth, and respiratory airways, sputum, stool, skin, gastric secretions, oropharyngeal swabs, nasopharyngeal swabs, throat swabs, peri-rectal swabs, rectal swabs, vaginal swabs, nasal aspirates, nasal wash, renal tissue, and fluid therefrom including perfusion media, pure cultures of bacterial fungal isolates, fluids and cells obtained by the perfusion of tissues of both human and animal origin, and fluids and cells derived from the culturing of human cells, including human stem cells and human cartilage or fibroblasts, pure cultures of bacterial fungal isolates, and swabs or washes of environmental surfaces, or other samples derived from environmental surfaces or other samples derived from environmental surfaces.

### Claim 36 (depends on 34)

The method of claim 34, wherein the GBS-associated colonization, condition, syndrome or disease is selected from the group consisting of: urinary tract infection, meningitis, pneumonia, chorioamnionitis, endometritis, endocarditis, skin infections, such as boils, impetigo, cellulitis, and scalded skin syndrome; bacteremia, resulting in a persistent fever and other signs of blood poisoning; fever, nausea, vomiting, rash on palms and soles, confusion, muscle aches, seizures, headache; bone and joint infections; septic arthritis, resulting in joint swelling, severe pain in the affected joint, fever and shaking chills; early onset disease in infants, resulting in fever, difficulty and lethargy and late-onset disease in infants, resulting in coughing, congestion, fever, difficulty feeding, lethargy and seizures.

### Claim 37

A kit for binding, amplifying and sequencing a GBS sequence in a sample, comprising:
a) at least one forward primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33; and
b) at least one reverse primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35; and
c) reagents for the sequencing of amplified DNA fragments.

### Claim 38 (depends on 37)

The kit of claim 37, further comprising a positive control and/or a process control and/or a negative control.

### Claim 39 (depends on 37)

The kit of claim 37, further comprising reagents for quantitating, monitoring and/or screening a GBS sequence in a sample.

### Claim 40

A method of diagnosing a GBS-associated colonization, condition, syndrome or disease, comprising contacting a denatured target from a sample with one or more probes comprising a sequence selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions for hybridization to occur;
wherein hybridization of the one or more probes to a denatured target is indicative of the presence of GBS in the sample.

### Claim 41 (depends on 40)

The method of claim 40, wherein the sample is selected from the group consisting of: blood, serum, plasma, enriched peripheral blood mononuclear cells, fecal material, urine, neoplastic or other tissue obtained from biopsies, cerebrospinal fluid, saliva, fluids collected from the ear, eye, mouth, and respiratory airways, sputum, stool, skin, gastric secretions, oropharyngeal swabs, nasopharyngeal swabs, throat swabs, peri-rectal swabs, rectal swabs, vaginal swabs, nasal aspirates, nasal wash, renal tissue, and fluid therefrom including perfusion media, pure cultures of bacterial fungal isolates, fluids and cells obtained by the perfusion of tissues of both human and animal origin, and fluids and cells derived from the culturing of human cells, including human stem cells and human cartilage or fibroblasts, pure cultures of bacterial fungal isolates, and swabs or washes of environmental surfaces, or other samples derived from environmental surfaces or other samples derived from environmental surfaces.

### Claim 42 (depends on 40)

The method of claim 40, wherein the GBS-associated colonization, condition, syndrome or disease is selected from the group consisting of: urinary tract infection, meningitis, pneumonia, chorioamnionitis, endometritis, endocarditis, skin infections, such as boils, impetigo, cellulitis, and scalded skin syndrome; bacteremia, resulting in a persistent fever and other signs of blood poisoning; fever, nausea, vomiting, rash on palms and soles, confusion, muscle aches, seizures, headache; bone and joint infections; septic arthritis, resulting in joint swelling, severe pain in the affected joint, fever and shaking chills; early onset disease in infants, resulting in fever, difficulty and lethargy and late-onset disease in infants, resulting in coughing, congestion, fever, difficulty feeding, lethargy and seizures.

### Claim 43

A method for identifying the causative agent of early-onset and/or late-onset disease in infants by detecting one or more GBS strains in a sample based on its gene(s), the method comprising:
a) contacting the sample with at least one forward primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33 and at least one reverse primer selected from the group consisting of SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35 under conditions such that nucleic acid amplification occurs to yield an amplicon; and
b) contacting the amplicon with one or more probes comprising one or more sequences selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34 under conditions such that hybridization of the probe to the amplicon occurs;
wherein the hybridization of the probe is indicative of GBS in the sample.

### Claim 44 (depends on 43)

The method of claim 43, wherein gene(s) selected from the group consisting of: neuA and/or cspA and/or cylE and/or hylB and/or mreA and/or pstl.

### Claim 45

A screening kit for binding and amplifying a GBS sequence, comprising:
a) at least one forward primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 1, 4, 8, 11, 14, 19, 22, 25, 30 and 33; and
b) at least one reverse primer comprising the sequence selected from the group consisting of: SEQ ID NOS: 3, 6, 7, 10, 13, 16, 18, 21, 24, 27, 29, 32 and 35.

### Claim 46 (depends on 45)

The kit of claim 45, further comprising a probe having a sequence selected from the group consisting of: SEQ ID NOS: 2, 5, 9, 12, 15, 17, 20, 23, 26, 28, 31 and 34.

### Claim 47 (depends on 45)

The kit of claim 45, further comprising a positive control and/or a process control and/or a negative control.

### Claim 48 (depends on 47)

The kit of claim 47, wherein the positive control is a sequence comprising SEQ ID NO: 36.

### Claim 49 (depends on 47)

The kit of claim 47, wherein the process control is detected by a forward primer comprising a sequence selected from the group consisting of SEQ ID NOS: 37, 40, 43, 46, 53 and 56, a reverse primer selected from the group consisting of SEQ ID NOS: 39, 42, 45, 48, 49, 50, 51, 52, 55 and 58 and a probe selected from the group consisting of SEQ ID NOS: 38, 41, 44, 47, 54 and 57.

### Claim 50 (depends on 38)

The kit of claim 38, wherein the process control is detected by a forward primer comprising a sequence selected from the group consisting of SEQ ID NOS: 37, 40, 43, 46, 53 and 56, a reverse primer selected from the group consisting of SEQ ID NOS: 39, 42, 45, 48, 49, 50, 51, 52, 55 and 58 and a probe selected from the group consisting of SEQ ID NOS: 38, 41, 44, 47, 54 and 57.

### Claim 51 (depends on 28)

The kit of claim 28, wherein the process control is detected by a forward primer comprising a sequence selected from the group consisting of SEQ ID NOS: 37, 40, 43, 46, 53 and 56, a reverse primer selected from the group consisting of SEQ ID NOS: 39, 42, 45, 48, 49, 50, 51, 52, 55 and 58 and a probe selected from the group consisting of SEQ ID NOS: 38, 41, 44, 47, 54 and 57.
